This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Sanofi-Aventis's Tender Offer for Genzyme
Eades, Kenneth M.; Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1716-EFinanceIn October 2010, Henri Termeer, the chairman and CEO of Genzyme, received a letter from the CEO of Sanofi-Aventis announcing its intention to commence a tender offer for Genzyme. Termeer thought the offer undervalued Genzyme, given the number of promising new drugs in the company’s pipeline and the success of its current drug portfolio. The case focuses on the strategic and financial considerations of a large corporate acquisition. To estimate Ge...Starting at €8.20
-
The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1715-EFinanceThis case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme’s pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (C...Starting at €8.20
-
Genzyme and Relational Investors: Science and Business Collide? - Teaching Note
Eades, Kenneth M.; Matos, PedroTeaching Note DARDEN-F-1660TN-EFinanceTeaching note for product F-1660Starting at €0.00
-
Barclays Global Investors and Exchange Traded Funds
Viceira, Luis M.; Wagonfeld, Alison BerkleyCase HBS-208033-EFinanceProvides an overview of the Exchange Traded Funds (ETF) industry and highlights the leadership role that Barclays Global Investors (BGI) has played in this developing asset class. BGI launched its first ETFs under the iShares brand name in 2000, and by mid-2007 BGI was the global leader in the $600 billion ETF market. BGI's success had started attracting the interest of other large asset management firms, and Lee Kranefuss, CEO of BGI's iShares b...Starting at €8.20
-
Dominion Gas Holdings, LLC-Anticipatory Interest Rate Hedging
Matos, Pedro; Maiden, Stephen E.Case DARDEN-F-1754-EFinanceThe case examines interest rate risk management at a U.S. utility company, Dominion Gas Holdings. In November 2012, as part of its new financing plan, it wanted to hedge the interest rate risk involved with the company’s 2013 planned issuance of $1 billion in debt. While the coupon rates for the planned debt were unknown as of November 2012, the company wanted to lock in its financing costs one year ahead since interest rates were at historically...Starting at €8.20
-
S&P Indices and the Indexing Business in 2012
Viceira, Luis M.; Wagonfeld, Alison BerkleyCase HBS-213049-EFinanceIn June 2012, Standard & Poor's Indices is finalizing a deal with the CME Group, the largest global exchange for futures and options and majority owner of Dow Jones Indexes, to combine their respective indices business into a new joint venture called S&P Dow Jones Indices. This case discusses the index provider business model through the lenses of this transaction: sources of revenue and profitability, business valuation, uses of indexes in the m...Starting at €8.20
-
Genzyme and Relational Investors: Science and Business Collide?
Eades, Kenneth M.; Matos, Pedro; Green, RickCase DARDEN-F-1660-EFinanceThe chairman and CEO of the Genzyme Corporation, one of the country’s top five biotechnology firms, has received a phone call requesting a meeting with the cofounder and principal of a large activist investment fund that now has a 2.6% stake in his company. Before meeting with him, the CEO is aware that he needs a strategy for dealing with this “activist” investor with a track record of forcing out CEOs.Starting at €8.20
-
Embrace
Chu, Michael; Bloom, David E.; Wagonfeld, Alison BerkleyCase HBS-814001-EEntrepreneurshipStarting at €8.20
-
Nanosolar, Inc.
Steenburgh, Thomas; Wagonfeld, Alison BerkleyCase HBS-510037-EMarketingNanosolar is a start-up company in the clean tech sector. It expects to be one of the first manufacturers to produce thin-film solar panels using copper indium gallium (di)selenide (CIGS) technology. Although this technology is less efficient in producing electricity than polysilicone, it is much less costly too. As it is about to enter the market, Nanosolar is facing the decision on which market to enter. Should it attempt to go into the Europea...Starting at €8.20
-
Cisco in 2012
Gulati, Ranjay; Wagonfeld, Alison Berkley; Silvestri, LucianaCase HBS-413069-ELeadership and People ManagementIn 2012, Cisco was under intense pressure to show results: growth in its core business was decelerating and a number of exploratory ventures and acquisitions had not proven as profitable as expected. CEO John Chambers vowed to restore the company's health in a way that would support the agility and entrepreneurial mindset required to be successful in emerging sectors while continuing to achieve efficiency and profitability in Cisco's core busines...Starting at €8.20